Clinical trial
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or…
NCT00095693 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00095693 |
|---|---|
| Title | Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer |
| Official title | Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage III Follicular Thyroid Cancer, Stage III Papillary Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer |
| Intervention type | Drug, Other, Procedure, Radiation |
| Interventions | sorafenib tosylate, laboratory biomarker analysis, pharmacological study, fludeoxyglucose F 18, positron emission tomography, dynamic contrast-enhanced magnetic resonance imaging |
| Enrollment | 25 |
| Start date | Oct 1, 2004 |
| Primary completion | Aug 1, 2005 |
| Completion | Dec 1, 2011 |
| First posted | Nov 8, 2004 |
| Last update posted | Jan 16, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: